Skip to main content
. 2011 Jun 15;13(3):R67. doi: 10.1186/bcr2907

Figure 2.

Figure 2

Prognostic value of circulating tumor cells according with different first-line treatments. Estimated progression-free survival and overall survival according to baseline circulating tumor cell (CTC) value (< 5 vs. ≥ 5) in patients receiving (a), (e) endocrine therapy, (b), (f) chemotherapy alone, (c), (g) chemotherapy + bevacizumab, and (d), (h) chemotherapy + human epidermal growth factor receptor-2 (HER-2)-targeting drugs. C.I., confidence interval.